Valuation: Ovid Therapeutics Inc.

Market Cap 43Cr 38Cr 35Cr 32Cr 61Cr 4.15TCr 62Cr 416.06Cr 162.95Cr 2.07TCr 163.35Cr 159.73Cr 6.82TCr P/E 2026 *
-4.82x
P/E 2027 * -4.44x
Enterprise Value 43Cr 38Cr 35Cr 32Cr 61Cr 4.15TCr 62Cr 416.06Cr 162.95Cr 2.07TCr 163.35Cr 159.73Cr 6.82TCr EV / Sales 2026 *
4,045x
EV / Sales 2027 * 2,609x
Free-Float
92.96%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day+4.95%
1 week-0.85%
Current month+4.95%
1 month-13.38%
3 months-16.49%
6 months+50.32%
Current year+42.94%
1 week 2.2
Extreme 2.2
2.4
1 month 2.2
Extreme 2.2
2.82
Current year 1.36
Extreme 1.36
3.1
1 year 0.48
Extreme 0.477
3.1
3 years 0.24
Extreme 0.2425
4.14
5 years 0.24
Extreme 0.2425
4.2
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 01/01/2026
Director of Finance/CFO 59 06/07/2026
Chief Tech/Sci/R&D Officer 60 02/12/2025
Director TitleAgeSince
Chairman 72 01/04/2014
Director/Board Member 81 23/11/2015
Director/Board Member 61 14/06/2017
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Free

Chief Financial Officer

50,000 0.0268%
06/07/26 Other

Chief Financial Officer

4,50,625 0.2414%
07/04/26 Free

Director

17,578 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
+4.95%-0.85%+366.00%-29.82% 43Cr
+0.05%+3.08%+38.17%+66.77% 5.67TCr
-3.06%-8.56%+23.62%+58.73% 5.2TCr
+1.84%+1.27%-14.06%-13.50% 2.33TCr
-0.15%-6.00%-9.42%+344.47% 2.13TCr
-0.67%-3.25%+33.09%-29.84% 1.74TCr
+9.91%-2.51%+188.84%+326.19% 1.48TCr
+3.83%-1.34%+47.77%+165.22% 1.38TCr
+1.61%+0.56%+439.92%+166.12% 1.21TCr
+3.14%-12.56%+59.51%+149.39% 1.11TCr
Average +2.15%-2.12%+117.35%+120.37% 2.23TCr
Weighted average by Cap. +0.57%-1.85%+58.47%+108.13%

Financials

2026 *2027 *
Net sales 1L 93.43T 87.23T 80.07T 2L 1.02Cr 2L 10.29L 4L 51.1L 4L 4L 1.69Cr 2L 1L 1L 1L 2L 1.59Cr 2L 15.95L 6L 79.22L 6L 6L 2.61Cr
Net income -7.71Cr -6.7Cr -6.26Cr -5.74Cr -11Cr -735.09Cr -11Cr -74Cr -29Cr -366.58Cr -29Cr -28Cr -1.21TCr -8.96Cr -7.79Cr -7.27Cr -6.67Cr -13Cr -853.83Cr -13Cr -86Cr -34Cr -425.79Cr -34Cr -33Cr -1.4TCr
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
03/26/03 $2.330 +4.95% 16,77,481
31/26/31 $2.220 -6.33% 17,45,353
30/26/30 $2.370 +3.49% 12,86,380
29/26/29 $2.290 -2.97% 6,48,338
28/26/28 $2.360 +0.43% 13,51,124
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.330USD
Average target price
5.693USD
Spread / Average Target
+144.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock